This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Gildan, HanesBrands have product overlaps, but also viable antitrust defenses

By Ilana Kowarski ( September 22, 2025, 18:41 GMT | Comment) -- Clothing manufacturer Gildan Activewear’s proposed buyout of rival HanesBrands would unify two key global suppliers of affordable, neutral fashion essentials  — creating numerous product overlaps for competition authorities to examine. However, the merging parties are likely to argue that entry barriers in their sector are low and that they face significant competitive pressure from other low-end and mid-tier apparel makers.Clothing manufacturer Gildan Activewear’s proposed buyout of rival HanesBrands would unify two key global suppliers of affordable, neutral fashion essentials  — creating numerous product overlaps for competition authorities to examine. However, the merging parties are likely to argue that entry barriers in their sector are low and that they face significant competitive pressure from other low-end and mid-tier apparel makers....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login